Over the past month, the World Health Organization and the Access to Medicines Foundation issued reports bemoaning an overall lack of private investment and innovation in antibiotic development, especially novel antimicrobials needed to overcome pathogens that are resistant to existing treatments. Toward that end, the WHO has been working for the past few months with the European Investment Bank to create an investment fund with up to $1 billion to finance antimicrobials that have new mechanisms of action. The effort is still getting organized and may not debut for several months, but WHO and EIB officials are hopeful it will yield at least 10 useful medications. We spoke with Peter Beyer, a senior adviser in the WHO antimicrobial resistance division, about the progress. This is an edited version of our conversation.

Pharmalot: Where did the impetus for this fund come from?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Hi Ed,

    Can the WHO compel Gilead to issue compulsory license regardless of patent status for Remdisivir if the current clinical trials in China prove it to be effective? If yes, then the funding can focus solely on “scale up” and eventual large industrial level quantity manufacturing instead of discovering something from scratch!

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy